Glenmark Pharmaceuticals on Thursday said it has become the first company in India to receive approval from DCGI to conduct clinical trials of Favipiravir antiviral tablets to treat COVID-19 patients. Having internally developed the API and the formulations for the product, the company received approval for conducting the trial on mild to moderate patients.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/3bQLFQg
